Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Rosetta Genomics Ltd. is a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP). Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008.

Part of The Mcclay Foundation, Almac Diagnostic Services Ltd. is a company headquartered in Craigavon, UK. The firm engages in development of cancer diagnostics.\nThe company says this about itself: Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. The company, based in Craigavon, UK and Durham, USA has been in existence for over 15 years. Our diagnostic experience spans: Oncology, Immunology, CNS and Infective diseases.

DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk. Its mission is to advance the health and wellbeing of people with, or at risk for, diabetes through simple, cost-effective, and easily accessible diabetes care. Their goal is to develop and provide point-of-care testing capabilities that are especially useful in alleviating the substantial economic and public health burden of diabetes. DiabetOmics was founded in 2008 and is headquartered in Beaverton, Oregon.

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

miR Scientific LLC is an American private company located in New York, NY. The firm develops disease management platform to gives providers and patients first-time access to actionable health data, illuminating a clear path to cancer management. It was founded in 2014 by Rob Tenniswood, Sam Salman and Martin Tenniswood. Sam Salman has been the CEO since the company founding.\nThe company says this about itself: miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform��, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform powers the miR Sentinel�� Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from non-DRE urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Biotheranostics is a commercial-stage molecular diagnostics company that develops and provides diagnostic, prognostic, and predictive tests that support physicians in the treatment of cancer patients. Biotheranostics is a leader in the development of evidence-based biomarkers to address unmet medical needs, and the Company has set the foundation for rapid growth. The company is based in San Diego, California, and offers testing services through its CLIA-certified, CAP-accredited laboratory that is directly licensed or otherwise authorized to perform testing in all 50 states.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Gentofte Hospital (Copenhagen University Hospital Gentofte) is located in Gentofte within Copenhagen in Denmark. Administratively, it is part of the hospital service of Region Hovedstaden. The hospital primarily serves the municipalities of Gentofte, Lyngby-Taarbæk, and Rudersdal, with a population of about 175,000.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Rigshospitalet (meaning The National, State or Kingdom Hospital, but not usually translated) is one of the largest hospitals in Denmark and the most highly specialised hospital in Copenhagen. The hospital's main building is a 16 storey functionalist highrise, one of the tallest structures in the central parts of the city. Rigshospitalet neighbours the Panum Building which houses the Faculty of Health and Medical Sciences at the University of Copenhagen. As a teaching hospital it is part of the framework organisation Copenhagen University Hospital.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.